NEJM This Week — March 26, 2026 @NEJMgroup

Uploaded March 2026 | Updated September 2026, 1 week ago

This week, we present new clinical trials on immunotherapy for stage III mismatch repair–deficient colon cancer, early surgery for asymptomatic aortic stenosis, an approach to dengue virus suppression, and advances in gene and prime-editing therapies for rare disorders. We also review minipuberty. We follow the case of a 12-year-old girl with altered mental status and persistent hypoglycemia, and we explore Perspectives on corporate influences on health, vaccine communication, antitrust policy, conflicts of interest, and the meaning of the number needed to treat.

Cardiovascular Risk Factors — Hypertension | NEJM

60-Second Journal Club: Randomized Trial of Sedative Choice for Intubation

$Ask the Expert: Why Do HFpEF Patients Experience Shortness of Breath? Neha J. Pagidipati, MD, and Donald Lloyd-Jones, MD, discuss common symptoms of heart failure with preserved ejection fraction (HFpEF) and why they occur. Watch “HFpEF Explained — Living with HFpEF,” part three in a three-part Double Take video miniseries, now available on our YouTube channel.$

$HFpEF Explained — Managing HFpEF in Primary Care | NEJM In this second episode of a three-part Double Take miniseries on heart failure with preserved ejection fraction (HFpEF) from the New England Journal of Medicine, Drs. Shah, Khan, Pagidipati, and Lloyd-Jones describe pharmacologic and nonpharmacologic interventions for patients with HFpEF. They discuss how selected drug therapies can also address common coexisting conditions, such as hypertension and diabetes. The importance of monitoring and of implementing individualized lifestyle modifications is highlighted in the video. For further reading, the following articles, referenced in this video, are available at NEJM.org: Empagliflozin in Heart Failure with a Preserved Ejection Fraction (Anker et al., in the October 14, 2021, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2107038 ); Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (Solomon et al., in the October 24, 2024, issue, https://www.nejm.org/doi/10.1056/NEJMoa2407107 ); Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (Kosiborod et al., in the September 21, 2023, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2306963 ); Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (Packer et al., in the January 30, 2025, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2410027 ); and Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (Solomon et al., in the September 22, 2022, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2206286 ). Funding for this Double Take is provided by the Doris Duke Foundation, committed to building a creative, equitable, and sustainable future. #medicaleducation #clinicalmedicine #nejm The New England Journal of Medicine is the world’s leading general medical journal. Continuously published for over 200 years, the Journal publishes peer-reviewed research along with interactive clinical content for physicians, educators, and the global medical community at NEJM.org.$

Dr. Noha Aboelata on the Pulse Oximeter Problem

Perioperative Apalutamide in High-Risk Localized Prostate Cancer (PROTEUS)

Response-Tailored Antibiotic Treatment for Endocarditis (POET II)